Morgan Stanley Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $50
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
Buy Rating Affirmed for Zai Lab on Robust Drug Sales Growth and Strong Market Position
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Announces Target Price $25
Buy Rating Affirmed for Zai Lab on Strong Financials and Promising Pipeline Developments
Zai Lab Analyst Ratings
Bank of America Securities Sticks to Their Buy Rating for Zai Lab (ZLAB)
JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating
Zai Lab Analyst Ratings
Zai Lab Analyst Ratings
Zai Lab Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Zai Lab (ZLAB), Alphatec Holdings (ATEC)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
Buy Rating Affirmed for Zai Lab Amid Strong Sales Performance and Positive Development Outlook
Zai Lab Analyst Ratings
Buy Rating on Zai Lab With a Target Price of $66 Amid Vyvgart's Growth Potential and Strategic Positioning
Buy Rating Affirmed for Zai Lab on Strong Product Performance and Upbeat Revenue Projections
Zai Lab's Growth and Pipeline Prompts Buy Rating: Analyst David Li's Financial Outlook and Price Objective
Analysts' Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Globus Medical (GMED) and Zai Lab (ZLAB)
No Data
No Data